MA31761B1 - Nouveaux inhibiteurs de seh et leur utilisation - Google Patents

Nouveaux inhibiteurs de seh et leur utilisation

Info

Publication number
MA31761B1
MA31761B1 MA32751A MA32751A MA31761B1 MA 31761 B1 MA31761 B1 MA 31761B1 MA 32751 A MA32751 A MA 32751A MA 32751 A MA32751 A MA 32751A MA 31761 B1 MA31761 B1 MA 31761B1
Authority
MA
Morocco
Prior art keywords
seh
relates
compounds
compound
treatment
Prior art date
Application number
MA32751A
Other languages
Arabic (ar)
English (en)
Inventor
Yun Ding
Reema K Thalji
Joseph Paul Marino Jr
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA31761B1 publication Critical patent/MA31761B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne de nouveaux inhibiteurs de seh et leur utilisation dans le traitement de maladies médiées par l'enzyme seh. De façon spécifique, l'invention concerne des composés répondant à la formule i : r1, r2, r5, r6, a, b, y, z, n, et m étant définis ci-après, et des sels pharmaceutiquement acceptables de ces composés. Les composés de l'invention sont des inhibiteurs de seh et peuvent être utilisés dans le traitement de maladies médiées par l'enzyme seh, telles que l'hypertension. Par conséquent, l'invention concerne également des compositions pharmaceutiques contenant un composé de l'invention. L'invention concerne de plus des procédés d'inhibition de seh et le traitement de pathologies y étant associées au moyen d'un composé de l'invention ou d'une composition pharmaceutique contenant un composé de l'invention.
MA32751A 2007-10-11 2010-04-08 Nouveaux inhibiteurs de seh et leur utilisation MA31761B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915407P 2007-10-11 2007-10-11
PCT/US2008/079517 WO2009049157A1 (fr) 2007-10-11 2008-10-10 Nouveaux inhibiteurs de seh et leur utilisation

Publications (1)

Publication Number Publication Date
MA31761B1 true MA31761B1 (fr) 2010-10-01

Family

ID=40549589

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32751A MA31761B1 (fr) 2007-10-11 2010-04-08 Nouveaux inhibiteurs de seh et leur utilisation

Country Status (28)

Country Link
US (2) US8173805B2 (fr)
EP (1) EP2214487B1 (fr)
JP (1) JP5372943B2 (fr)
KR (1) KR101546111B1 (fr)
CN (1) CN101896065B (fr)
AU (1) AU2008310732B2 (fr)
BR (1) BRPI0817542A2 (fr)
CA (1) CA2702265C (fr)
CO (1) CO6270285A2 (fr)
CR (1) CR11423A (fr)
CY (1) CY1114865T1 (fr)
DK (1) DK2214487T3 (fr)
DO (1) DOP2010000101A (fr)
EA (1) EA018414B1 (fr)
ES (1) ES2445444T3 (fr)
HR (1) HRP20140105T1 (fr)
IL (1) IL204889A (fr)
MA (1) MA31761B1 (fr)
MX (1) MX2010003942A (fr)
MY (1) MY157116A (fr)
NZ (1) NZ584471A (fr)
PL (1) PL2214487T3 (fr)
PT (1) PT2214487E (fr)
RS (1) RS53180B (fr)
SI (1) SI2214487T1 (fr)
UA (1) UA107444C2 (fr)
WO (1) WO2009049157A1 (fr)
ZA (1) ZA201002465B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994317B2 (en) 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
WO2009049165A1 (fr) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Inhibiteurs inédits de la seh et leur utilisation
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015104422A1 (fr) 2014-01-13 2015-07-16 Basf Se Composés dihydrothiophène dans la lutte contre des nuisibles invertébrés
WO2015155129A1 (fr) * 2014-04-07 2015-10-15 Basf Se Composé de diaminotriazine
WO2016058544A1 (fr) 2014-10-16 2016-04-21 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
WO2020074549A1 (fr) * 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques topiques destinées au traitement de dysfonctionnements microvasculaires de la peau
EP4618985A1 (fr) 2022-11-18 2025-09-24 Universitat De Barcelona Inhibiteurs doubles de récepteur sigma-1 et d'époxyde hydrolase soluble et leur utilisation dans le traitement de la douleur
WO2024105225A1 (fr) 2022-11-18 2024-05-23 Universitat De Barcelona Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur
WO2026058000A2 (fr) 2024-09-13 2026-03-19 Ucl Business Ltd Procédés

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420283A (en) * 1993-08-02 1995-05-30 Pfizer Inc. Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide
WO2000038683A1 (fr) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company INHIBITEURS DU FACTEUR Xa OU DE LA THROMBINE
EP1790344B1 (fr) * 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Traitement de neuropathie périphérique induit par une pathologie et des tats connexés
US6451814B1 (en) * 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
US20020091133A1 (en) * 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
CA2449486A1 (fr) * 2001-06-29 2003-01-09 Boehringer Ingelheim Pharmaceuticals Inc. Procede d'utilisation d'inhibiteurs d'hydrolase epoxyde solubles
US20030055249A1 (en) 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
KR100875362B1 (ko) * 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
EP1505972A2 (fr) 2002-05-16 2005-02-16 Pharmacia Corporation Methodes de traitement de maladies et de troubles respiratoires avec un inhibiteur inos selectif et un inhibiteur pde et compositions a cet effet
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
EP1638955A2 (fr) * 2003-07-02 2006-03-29 Vertex Pharmaceuticals Incorporated Pyrimidines utilisees comme modulateurs des canaux ioniques sensibles au voltage
WO2005028467A1 (fr) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Composes heteroaromatiques et aromatiques a substitution 3,5-diaminopiperidine antibacteriens
AU2004274309B2 (en) * 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
WO2006037117A1 (fr) * 2004-09-27 2006-04-06 Amgen Inc. Composes heterocycliques substitues et procedes d'utilisation
WO2006053109A1 (fr) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes heteroaryle
EP1831181A2 (fr) 2004-12-14 2007-09-12 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase erk et utilisations
WO2006121719A2 (fr) * 2005-05-06 2006-11-16 Boehringer Ingelheim International, Gmbh Inhibiteurs de l'epoxyde hydrolase soluble et leurs methodes d'utilisation
CA2622754A1 (fr) * 2005-10-07 2007-04-19 Boehringer Ingelheim International Gmbh Composes de pyridinone ou pyrimidinone n-substitues utiles en tant qu'inhibiteurs d'epoxyde hydrolase soluble
WO2007098352A2 (fr) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Pyridineamides substitués pouvant être employés en tant qu'inhibiteurs d'époxyde hydrolase soluble
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
US7994317B2 (en) * 2006-11-03 2011-08-09 GlaxoSmithKline, LLC sEH inhibitors and their use
WO2009049154A1 (fr) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Nouveaux inhibiteurs de seh et leur utilisation
JP5372943B2 (ja) 2007-10-11 2013-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびそれらの使用
WO2009049165A1 (fr) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Inhibiteurs inédits de la seh et leur utilisation
JPWO2009048154A1 (ja) 2007-10-12 2011-02-24 日本電気株式会社 半導体装置及びその設計方法
WO2009070497A1 (fr) 2007-11-28 2009-06-04 Smithkline Beecham Corporation Inhibiteurs de ehs et de 11β-hsd1 et leur utilisation
EP2224928A4 (fr) 2007-12-06 2012-02-15 Glaxosmithkline Llc Nouveaux inhibiteurs de seh et leur utilisation
WO2009097474A1 (fr) 2008-01-30 2009-08-06 Smithkline Beecham Corporation Nouveaux inhibiteurs de seh et leur utilisation
EP2240025A4 (fr) * 2008-01-30 2012-03-28 Glaxosmithkline Llc NOUVEAUX INHIBITEURS DE sEH ET LEUR UTILISATION
WO2009097476A1 (fr) 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOUVEAUX INHIBITEURS DE sEH ET LEUR UTILISATION
WO2010011917A1 (fr) 2008-07-25 2010-01-28 Glaxosmithkline Llc Inhibiteurs doubles de seh et 11β-hsd1

Also Published As

Publication number Publication date
EA018414B1 (ru) 2013-07-30
UA107444C2 (uk) 2015-01-12
CN101896065A (zh) 2010-11-24
ZA201002465B (en) 2010-12-29
ES2445444T3 (es) 2014-03-03
US20100249137A1 (en) 2010-09-30
BRPI0817542A2 (pt) 2014-10-07
EA201070442A1 (ru) 2010-10-29
JP5372943B2 (ja) 2013-12-18
IL204889A0 (en) 2010-11-30
MX2010003942A (es) 2010-04-30
US8173805B2 (en) 2012-05-08
NZ584471A (en) 2012-01-12
HRP20140105T1 (hr) 2014-03-14
AU2008310732B2 (en) 2012-03-08
CA2702265C (fr) 2014-12-02
EP2214487B1 (fr) 2013-11-27
DOP2010000101A (es) 2010-07-31
CA2702265A1 (fr) 2009-04-16
US8212032B2 (en) 2012-07-03
CO6270285A2 (es) 2011-04-20
CN101896065B (zh) 2013-12-18
HK1141211A1 (en) 2010-11-05
RS53180B (sr) 2014-06-30
CR11423A (es) 2010-06-28
WO2009049157A1 (fr) 2009-04-16
CY1114865T1 (el) 2016-12-14
AU2008310732A1 (en) 2009-04-16
SI2214487T1 (sl) 2014-03-31
JP2011500594A (ja) 2011-01-06
PT2214487E (pt) 2014-02-20
EP2214487A1 (fr) 2010-08-11
EP2214487A4 (fr) 2011-12-21
DK2214487T3 (da) 2014-02-10
PL2214487T3 (pl) 2014-04-30
US20100210656A1 (en) 2010-08-19
KR20100075619A (ko) 2010-07-02
IL204889A (en) 2014-08-31
MY157116A (en) 2016-05-13
KR101546111B1 (ko) 2015-08-20

Similar Documents

Publication Publication Date Title
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
RU2370495C2 (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
TNSN07022A1 (fr) Derives de pyridine
MA31419B1 (fr) Derives de pyridine
TN2009000138A1 (fr) Biaryl-ether-urees
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA29926B1 (fr) Derives de pyrazine
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA31373B1 (fr) Composes amino-heterocycliques
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA31319B1 (fr) Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA32231B1 (fr) Composés organiques
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA31894B1 (fr) Composes organiques
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31766B1 (fr) Composés organiques
MA30652B1 (fr) Composes organiques
MA31873B1 (fr) Inhibiteurs de la peptide déformylase